165 related articles for article (PubMed ID: 2910788)
61. [Serum tumor markers SCC, TATI and TPS: value in follow-up of females with cervix cancer].
Joura E; Gitsch G; Kainz C; Fröhlich B; Biegelmayr C; Kölbl H
Gynakol Geburtshilfliche Rundsch; 1992; 32 Suppl 1():115. PubMed ID: 1286308
[No Abstract] [Full Text] [Related]
62. Serum tumour markers in carcinoma of the uterine cervix and outcome following radiotherapy.
Sproston AR; Roberts SA; Davidson SE; Hunter RD; West CM
Br J Cancer; 1995 Dec; 72(6):1536-40. PubMed ID: 8519673
[TBL] [Abstract][Full Text] [Related]
63. Prognostic significance of squamous cell carcinoma (SCC) antigen in primary advanced and recurrent cervical carcinoma.
Meier W; Stieber P; Hasholzner U; Baumgartner L; Fateh-Moghadam A
Anticancer Res; 1997; 17(4B):2959-62. PubMed ID: 9329575
[TBL] [Abstract][Full Text] [Related]
64. [The monitoring of gynecological radiotherapy using serial tumor marker determinations].
Wagner RK; Atzinger A; Breit A
Strahlenther Onkol; 1990 Jul; 166(7):446-52. PubMed ID: 2200151
[TBL] [Abstract][Full Text] [Related]
65. Utility of the serum tumor markers: CYFRA 21.1, carcinoembryonic antigen (CEA), and squamous cell carcinoma antigen (SCC) in squamous cell lung cancer.
Tas F; Aydiner A; Topuz E; Yasasever V; Karadeniz A; Saip P
J Exp Clin Cancer Res; 2000 Dec; 19(4):477-81. PubMed ID: 11277326
[TBL] [Abstract][Full Text] [Related]
66. [Analysis of the levels of CA125, CA19-9, and CEA in the cervical mucus helps a diagnosis of cervical adenocarcinomas].
Fujii S; Konishi I; Nanbu Y; Sagawa N; Nonogaki H; Mori T
Nihon Sanka Fujinka Gakkai Zasshi; 1987 Dec; 39(12):2193-4. PubMed ID: 3480920
[No Abstract] [Full Text] [Related]
67. Prognostic value of pre-treatment circulating monocyte count in patients with cervical cancer: comparison with SCC-Ag level.
Lee YY; Choi CH; Sung CO; Do IG; Huh S; Song T; Kim MK; Kim HJ; Kim TJ; Lee JW; Kim BG; Bae DS
Gynecol Oncol; 2012 Jan; 124(1):92-7. PubMed ID: 22014631
[TBL] [Abstract][Full Text] [Related]
68. Study of a new tumor marker, CYFRA 21-1, in squamous cell carcinoma of the cervix, and comparison with squamous cell carcinoma antigen.
Tsai SC; Kao CH; Wang SJ
Neoplasma; 1996; 43(1):27-9. PubMed ID: 8843956
[TBL] [Abstract][Full Text] [Related]
69. Comparison of clinical behaviors and responses to radiation between squamous cell carcinomas and adenocarcinomas/adenosquamous carcinomas of the cervix.
Hong JH; Tsai CS; Wang CC; Lai CH; Chen WC; Lee SP; Chang TC; Tseng CJ
Chang Gung Med J; 2000 Jul; 23(7):396-404. PubMed ID: 10974754
[TBL] [Abstract][Full Text] [Related]
70. Prognostic significance of TPA versus SCC-Ag, CEA and neopterin in carcinoma of the uterine cervix.
Volgger B; Aspisirengil C; Genser-Krimbacher E; Ciresa-Koenig A; Daxenbichler G; Fuchs D; Windbichler G; Marth C
Cancer Lett; 2008 Apr; 262(2):183-9. PubMed ID: 18226853
[TBL] [Abstract][Full Text] [Related]
71. Evaluation of seven different tumour markers for the establishment of tumour marker panels in gynecologic malignancies.
Avall Lundqvist E; Nordström L; Sjövall K; Eneroth P
Eur J Gynaecol Oncol; 1989; 10(6):395-405. PubMed ID: 2627971
[TBL] [Abstract][Full Text] [Related]
72. The Diagnostic and Prognostic Value of Tumor Markers (CEA, SCC, CYFRA 21-1, TPS) in Head and Neck Cancer Patients.
Barak V; Meirovitz A; Leibovici V; Rachmut J; Peretz T; Eliashar R; Gross M
Anticancer Res; 2015 Oct; 35(10):5519-24. PubMed ID: 26408719
[TBL] [Abstract][Full Text] [Related]
73. Cyfra 21-1 in monitoring cervical cancer: a comparison with tissue polypeptide antigen and squamous cell carcinoma antigen.
Bonfrer JM; Gaarenstroom KN; Korse CM; Van Bunningen BN; Kenemans P
Anticancer Res; 1997; 17(3C):2329-34. PubMed ID: 9245246
[TBL] [Abstract][Full Text] [Related]
74. SCC antigen in the serum as an independent prognostic factor in operable squamous cell carcinoma of the cervix.
Strauss HG; Laban C; Lautenschläger C; Buchmann J; Schneider I; Koelbl H
Eur J Cancer; 2002 Oct; 38(15):1987-91. PubMed ID: 12376202
[TBL] [Abstract][Full Text] [Related]
75. [The clinical signifinace of CEA, Cyfra21-1 and SCC in laryngeal carcinoma's clinicopathological parameters].
Rao LH; Zhang L; Tian L; Yan JR; Xiang XY; Yu FB
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2017 Aug; 31(15):1182-1186. PubMed ID: 29798354
[No Abstract] [Full Text] [Related]
76. An evaluation of squamous cell carcinoma antigen in patients with cervical squamous cell carcinoma.
Senekjian EK; Young JM; Weiser PA; Spencer CE; Magic SE; Herbst AL
Am J Obstet Gynecol; 1987 Aug; 157(2):433-9. PubMed ID: 3475982
[TBL] [Abstract][Full Text] [Related]
77. [Tumor markers in uterine cancers].
Fukasawa I; Kousaka N; Kun Z; Inaba N
Gan To Kagaku Ryoho; 2002 Feb; 29(2):333-40. PubMed ID: 11865645
[TBL] [Abstract][Full Text] [Related]
78. [Tumor markers in patients with head-neck carcinomas].
Walther EK; Dahlmann N; Gorgulla HT
Laryngorhinootologie; 1990 May; 69(5):271-4. PubMed ID: 2354022
[TBL] [Abstract][Full Text] [Related]
79. A dual-label time-resolved fluorescence immunoassay for the simultaneous determination of carcinoembryonic antigen and squamous cell carcinoma antigen.
Mao Q; Liu X; Chen C; Ye J; Liang H; Li B; Sun X; Sun L; Sun Y; Mu X; Li L
Biotechnol Appl Biochem; 2018 Nov; 65(6):816-821. PubMed ID: 29679420
[TBL] [Abstract][Full Text] [Related]
80. Serum YKL-40 as a marker for cervical adenocarcinoma.
Mitsuhashi A; Matsui H; Usui H; Nagai Y; Tate S; Unno Y; Hirashiki K; Seki K; Shozu M
Ann Oncol; 2009 Jan; 20(1):71-7. PubMed ID: 18723551
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
